Summary.-The incidence of oncofoetal antigens has been reported to be increased in patients with gynaecological cancers. In this study the incidence of CEA, AFP, and hCG (, subunit) were studied in patients with adenocarcinoma of the ovary, adenocarcinoma of the cervix, and squamous-cell carcinoma of the cervix. Using a low cut-off point (CEA 2 5 ,ug/l, AFP 5 ,ug/l, and hCG 3 i.u./l) there is an unacceptably high proportion of control patients having one or more positive tests (42-54%) compared to cancer-bearing patients (67%). The specificity of the tests can be increased to over 95°, by increasing the cut-off point to CEA 10 ug/l, AFP 10 ,g/I, and hCG 10 i.u./l). Although this reduces the sensitivity considerably, the incidence of false positives in the control population is reduced to nil in non-cancer patients and to 2% in cancer patients tested when free of tumour, compared to 17% of patients with cancer of the ovary, 330% with adenocarcinoma of the cervix, and 6% with squamous-cell carcinoma of the cervix. Patients with adenocarcinoma of the cervix were clearly distinguishable from those with squamous -cell carcinoma of the cervix by these tests. There was also a significant correlation between AFP and hCG levels in adenocarcinoma of the cervix (r = 0 53, P < 0.05).
SEVERAL ATTEMPTS have been made to diagnose cancer using serological techniques. More recently, the use of simultaneous assays has enabled the detection of a higher proportion of patients (Franchimont et al., 1976; Coombes et al., 1980) . In gynaecological cancer, a number ofworkers have looked for raised levels of various cancer-related substances which may correlate with tumour activity, including carcinoembryonic antigen (CEA), o-foetoprotein (AFP), f subunit of human chorionic gonadotropin (hCG), human placental lactogen, isoenzymes, etc. (Seppala et al., 1975; Fishman, et al., 1975; Lin et al., 1975; Samaan et al., 1976; Rutanen & Seppala, 1978; Khoo et al., 1977 Khoo et al., , 1979a . In most of these studies, the predictive value of these tests is not clearly established. Moreover, in studies of this nature the use of a control group of patients is critical, since tumour markers such as AFP and hCG may be under the influence of hormones which may precede tumour development and may be active long after removal of the tumour. In this study we examine the value of the oncofoetal antigens (namely, CEA, AFP, and hCG) in patients with cancer of the ovary, squamous-cell carcinoma of the cervix, and adenocarcinoma of the cervix, and compare these findings with those in cancer patients who have been free of tumour for at least 1 year, as well as with age-matched non-tumour-bearing patients.
MATERIALS AND METHODS

Patients
This study comprised 84 patients with cancer of the ovary or cervix who were examined pre-operatively. There were 30 patients with cancer of the ovary, the histological diagnosis being serous adenocarcinoma (11) , endometrioid adenocarcinoma (6), mucinous adenocarcinoma (4), mixed tumour (4) and others (5). Most patients were in os with non-malignant gynae-bound fraction was separated by adding 2 ml itons were studied The age of PEG (200 g/l, w/v) and the precipitate atients in the various groups collected by centrifugation at 3000 g for 20 e min. Cross reactivity of the antisera with LH, FSH, and TSH was not significant, being ye distribution in patients 0 11, 0 -11, and 0 80% respectively. Inter-and studied intra-assay coefficients of variation at 9-5
Age (years) i.u./l were 7-6% and 11.6% respectively. The Age (year) Asensitivity of the assay was 0-025 i.u./l. From the analysis of predictive values, sensitivities, and specificities of these tests (Tables IV & V) , it can be seen that at low cut-off points the specificity is very poor, being about 61% for CEA and 46% for multiple tests. However, when the cut-off point for the various tests is raised, the specificity is increased to > 95%0. This is associated with a marked reduction in sensitivity (40-30%) and an associated It is of interest to note that there was a positive significant correlation between AFP and hCG levels in patients with adenocarcinoma of the cervix (r = 0-53, P> 0.05) but not in other tumours or with other parameters. There was no significant correlation between stage of the disease and the proportion of patients with high oncofoetal antigen levels.
DISCUSSION
The value of the detection of CEA in gynaecological cancer has been subjected to several studies. When a level of 2-5 ,ug/l is taken as the cut-off point, an unacceptably high false-positive rate is detected in normal controls, e.g. 11% (Van Nagell et al., 1975) , 18% (Donaldson et al., 1980) and 10% (Di Saia et al., 1977) . When a CEA level of 5,Lg/l is taken as the cut-off point, the proportion of patients with high levels varies from 63% in cancer of the ovary (Khoo et al., 1977 (Khoo et al., , 1979a Sarjadi et al., 1980) , 31% of cases of cancer of the corpus, 36% of patients with cancer of the cervix, and 36% of cancer of the ovary, compared to 0% in controls. Rutanen et al. (1978) , on the other hand, found an incidence of only 9-8% in patients with gynaecological cancer, with a maximal incidence in ovarian cancer (20%); squamous-cell carcinoma had 10%, adenocarcinoma of the cervix 19%, and endometrial carcinoma 7%. In our study we find that, when a CEA value of 2-5 ptg/l is taken as cut-off, 38% of controls have high values, compared to 54% of cancer patients. This figure is quite unacceptable. When, however, a cut-off point of 10 ug/l is taken, none of the control patients have a high value, compared to 8 % of cancer patients. 14% of adenocarcinoma of the cervix patients had high CEA lev-els, compared to 3% with squamous-cell carcinoma. Moreover, in a previous study we showed that in none of 36 patients with cancer of the endometrium was CEA> 5 ,ug/l (Cauchi et al., 1980) . This is in agreement with the findings of Franchimont et al. (1976 ), Hansen et al. (1974 ), and Stone et al. (1977 , who emphasize the importance of taking CEA> 10 /xg/l as the cut-off level.
AFP has also been investigated as a possible tumour marker in gynaecological cancer. Khoo et al. (1977) found that 17% of 108 patients with cancer of the ovary had AFP levels > 25 ,ug/l. In germ-cell tumours the level was usually > 200 ,ug/l. Donaldson et al. (1980) The value of multiple tumour markers to establish the diagnosis of gynaecological cancer depends also on the cut-off point for these markers. A number of workers have used a combination of CEA, AFP, and hCG to detect the presence of gynaecological cancer. Donaldson et al. (1980) found that -85% of gynaecological cancers have elevation of one or more of these cancer markers. However, the cut-off point taken by these authors Hg/l, hCG 5 0 i.u./l, and AFP 20 ,g/l) produced an unacceptably high level of false positives in control patients (31 %). This is due to the relatively low cut-off point for CEA and the unexplained high proportion of control patients (22%) with AFP> 20 ,ug/l. The reason for this high proportion of AFP positive patients is not clear. Seppala et al. (1975) measured these markers in advanced ovarian cancer and found high CEA in 21% of patients, only one of whom had high AFP and none raised hCG. Our data (Table V) show that, while a low cut-off point for these markers (namely CEA 2-5 ,ug/l, AFP 5 ,6gll, hCG 3 i.u./l) results in an unacceptably high false-positive rate in control patients (42-54%), using a higher cut-off point (CEA 10 pg/l, AFP 10 ,ug/l, hCG 10 i.u./l) produced none of the control patients and only 1/42 of tumour-free cancer patients with one or more positive tests, compared to 17% of cancer:bearing patients. Even higher values (33 %) were found in patients with adenocarcinoma of the cervix.
These studies emphasize the importance of establishing the upper levels of normal, not only for age-matched normal persons but also for tumour-free cancer patients, in view of the fact that factors, including hormone stimulation, might be operating in a cancer patient irrespective of the presence or absence of tumour. The finding that there is a significant correlation between AFP and hCG in patients with adenocarcinoma of the cervix would indicate that production of these hormone markers was the result of the same stimulus, which is not necessarily the tumour itself. Further studies of the relevance of hormone stimulation to high oncofoetal antigen levels are under way.
